Qlife Holding AB (QLIFE) AI Stock Analysis

Qlife Holding AB

(Nasdaq OMX AB:QLIFE)

Select Model

Rating:40Underperform

Price Target:SEK 1.00▼(-7.24% Downside)

Action:downgraded

Date:10/24/26

The score is held down primarily by very weak financial performance—deep unprofitability and substantial ongoing cash burn—despite recent revenue acceleration and an improved (now positive) equity position. Technicals add further pressure as the stock is in a strong downtrend with negative MACD and very oversold momentum readings. Valuation provides limited offset because negative earnings make the P/E less informative and there is no dividend yield support.

Positive Factors

Revenue accelerationThe sharp increase in trailing revenue indicates growing commercial activity and potential customer adoption of Qlife’s diagnostic offering. Although the base remains small, continued expansion could improve operating leverage and support a more scalable business model over the next several quarters.

Negative Factors

Severe unprofitabilityExtremely negative margins show that Qlife has not yet reached an economically sustainable level of operations. Persistent losses suggest revenue growth is currently insufficient to cover the cost base, limiting internal funding capacity and making successful scaling essential to future profitability.

Qlife Holding AB (QLIFE) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 31.13M
Dividend Yield: ―
Average Volume (3M): 65.74K
Price to Earnings (P/E): -0.6
Beta (1Y): 1.38
Revenue Growth: 226.89%
EPS Growth: 57.26%
Country: Sweden
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Qlife Holding AB Business Overview & Revenue Model

Company Description

Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehen...

How the Company Makes Money

Qlife Holding AB makes money primarily by commercializing its diagnostic platform and the associated consumables used to run tests. The core revenue model typically combines (1) sales or leasing of instrumentation (the analyzer/platform), and (2) rec...

Qlife Holding AB Financial Statement Overview

Summary

Financials are dominated by severe losses and cash burn despite strong TTM revenue growth off a small base. Income statement shows deeply negative margins and persistent net losses; cash flow remains materially negative with negative operating cash flow and free cash flow; the balance sheet improved with positive TTM equity but leverage is still high (debt-to-equity ~3.15x), implying continued financing/dilution risk if burn persists.

Income Statement

18Very Negative

Balance Sheet

28Negative

Cash Flow

16Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	863.00K	324.00K	50.00K	244.00K	17.99M	39.61M
Gross Profit	-13.73M	-18.11M	-158.00K	-6.31M	-10.75M	44.54M
EBITDA	-18.23M	-18.11M	-12.46M	-150.50M	-78.05M	-35.13M
Net Income	-20.30M	-20.56M	-55.98M	-159.96M	-93.14M	-38.80M
Balance Sheet
Total Assets	12.56M	9.63M	11.64M	39.05M	192.65M	193.44M
Cash, Cash Equivalents and Short-Term Investments	4.36M	1.42M	2.71M	1.66M	14.55M	73.46M
Total Debt	8.35M	14.44M	8.70M	20.25M	52.44M	4.72M
Total Liabilities	9.91M	17.14M	13.07M	62.17M	101.50M	30.26M
Stockholders Equity	2.65M	-7.51M	-1.43M	-23.12M	91.15M	132.50M
Cash Flow
Free Cash Flow	-10.92M	-21.49M	-54.17M	-62.64M	-90.67M	-52.82M
Operating Cash Flow	-18.24M	-21.49M	-37.37M	-41.80M	-47.73M	-26.05M
Investing Cash Flow	0	0	-16.80M	-20.84M	-42.94M	-26.77M
Financing Cash Flow	21.49M	20.19M	55.23M	49.00M	32.73M	106.02M

Qlife Holding AB Technical Analysis

Technical Analysis SentimentNegative

Last Price1.08

Price Trends

50DMA1.50Negative

100DMA1.71Negative

200DMA1.87Negative

Market Momentum

MACD-0.14Negative

RSI36.79Neutral

STOCH30.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 1.08 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.50, and below the 200-day MA of 1.87, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 36.79 is Neutral, neither overbought nor oversold. The STOCH value of 30.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:QLIFE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.67B	33.84	15.23%	1.41%	1.95%	-8.91%
SE:SECT.B	74Outperform	SEK 67.51B	105.81	30.26%	0.38%	13.94%	5.70%
SE:SEZI	57Neutral	SEK 532.17M	-5.46	-35.44%	―	18.56%	28.11%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ACARIX	40Underperform	SEK 223.04M	-5.29	-100.09%	―	65.82%	41.28%
SE:QLIFE	40Underperform	SEK 31.13M	-0.57	987.64%	―	226.89%	57.26%
SE:SCIB	39Underperform	SEK 174.38M	-0.78	-303.61%	―	51.21%	42.24%

* Healthcare Sector Average

Performance Comparison

SE:QLIFE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:QLIFE	Qlife Holding AB	1.08	-1.07	-49.72%
SE:CEVI	CellaVision AB	195.60	17.76	9.98%
SE:SEZI	Senzime AB	3.38	-2.45	-41.94%
SE:SCIB	SciBase Holding AB	12.35	-13.24	-51.74%
SE:SECT.B	Sectra AB Class B	346.00	49.17	16.56%
SE:ACARIX	Acarix AB	0.18	-0.10	-35.61%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026

Qlife Holding AB AI Stock Analysis